HAMILTON, ON and BOSTON, March 5,
2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc.
(Nasdaq: FUSN), a clinical-stage oncology company focused on
developing next-generation radiopharmaceuticals as precision
medicines, today announced that interim efficacy and safety data
from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in
patients with metastatic castration-resistant prostate cancer
(mCRPC) has been selected for a clinical trial poster presentation
at the American Association for Cancer Research (AACR) Annual
Meeting 2024, being held April 5-10
in San Diego, California.
Presentation at AACR Annual Meeting 2024:
Title: Preliminary efficacy and safety results from the
(TATCIST) trial: A PSMA-directed targeted alpha therapy with
FPI-2265 (225Ac-PSMA-I&T) for the treatment of
metastatic castration-resistant prostate cancer (mCRPC)
Session: Phase II Clinical Trials 1
Session Date and Time: Tuesday April 9, 2024, 9:00 a.m
– 12:30 p.m. PT
Location: Poster Section 49
Abstract Number: CT224
The poster will be available on Fusion's website following the
presentation. For more details about the AACR Annual Meeting,
please visit:
https://www.aacr.org/meeting/aacr-annual-meeting-2024/.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company
focused on developing next-generation radiopharmaceuticals as
precision medicines. Fusion connects alpha particle emitting
isotopes to various targeting molecules in order to selectively
deliver the alpha emitting payloads to tumors. Fusion's
clinical-stage development portfolio includes lead program,
FPI-2265, targeting prostate specific membrane antigen for
metastatic castration resistant prostate cancer currently in a
Phase 2 trial and novel targeted alpha therapies (TATs) including
next-generation antibody drug conjugates (ADCs). Fusion has a
collaboration with AstraZeneca to jointly develop novel TATs and
combination programs between Fusion's TATs and AstraZeneca's DNA
damage response inhibitors and immuno-oncology agents. Fusion has a
fully operational Good Manufacturing Practice compliant
state-of-the-art radiopharmaceutical manufacturing facility to meet
supply demand for the Company's growing pipeline of TATs. The
Company has strategic actinium supply agreements with Niowave, Inc.
and BWXT Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations & Corporate
Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-interim-data-from-the-phase-2-tatcist-clinical-trial-evaluating-fpi-2265-at-the-2024-aacr-annual-meeting-302080615.html
SOURCE Fusion Pharmaceuticals